Searched for: in-biosketch:true
person:orlows01
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity
,; Moussa, Anthony; Bennett, Michaela; Wall, Dmitri; Meah, Nekma; York, Katherine; Bokhari, Laita; Asfour, Leila; Rees, Huw; Abraham, Leonardo Spagnol; Asz-Sigall, Daniel; Basmanav, Fitnat Buket; Bergfeld, Wilma; Betz, Regina C; Bhoyrul, Bevin; Blume-Peytavi, Ulrike; Callender, Valerie; Chitreddy, Vijaya; Combalia, Andrea; Cotsarelis, George; Craiglow, Brittany; Dhurat, Rachita; Donovan, Jeff; Doroshkevich, Andrei; Eisman, Samantha; Farrant, Paul; Ferrando, Juan; Gadzhigoroeva, Aida; Green, Jack; Grimalt, Ramon; Harries, Matthew; Hordinsky, Maria; Irvine, Alan; Jolliffe, Victoria; Kaiumov, Spartak; King, Brett; Lee, Joyce; Lee, Won-Soo; Li, Jane; Lortkipanidze, Nino; McMichael, Amy; Mesinkovska, Natasha Atanaskova; Messenger, Andrew; Mirmirani, Paradi; Olsen, Elise; Orlow, Seth J; Ovcharenko, Yuliya; Piraccini, Bianca Maria; Pirmez, Rodrigo; Rakowska, Adriana; Reygagne, Pascal; Rudnicka, Lidia; Corralo, David Saceda; Senna, Maryanne; Shapiro, Jerry; Sharma, Pooja; Siliuk, Tatiana; Starace, Michela; Suchonwanit, Poonkiat; Takwale, Anita; Tosti, Antonella; Vañó-Galván, Sergio; Visser, Willem I; Vogt, Annika; Wade, Martin; Yip, Leona; Zhou, Cheng; Sinclair, Rodney
IMPORTANCE/UNASSIGNED:Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact. OBJECTIVE/UNASSIGNED:To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI). EVIDENCE REVIEW/UNASSIGNED:A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022. FINDINGS/UNASSIGNED:Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss. CONCLUSIONS AND RELEVANCE/UNASSIGNED:This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure various disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.
PMID: 38324292
ISSN: 2168-6084
CID: 5632682
An update on private equity acquisitions in dermatology, 2013 to 2022
Agarwal, Aneesh; Orlow, Seth J
PMID: 37863202
ISSN: 1097-6787
CID: 5614262
Nonprofit funding in dermatology: A cross-sectional analysis in the United States, 2015 to 2019 [Editorial]
Agarwal, Aneesh; Orlow, Seth J
PMCID:10316649
PMID: 37404247
ISSN: 2666-3287
CID: 5539152
Skin in the Game: An Analysis of Venture Capital Investment in Dermatology from 2002 to 2021
Agarwal, Aneesh; Orlow, Seth J
PMID: 36639307
ISSN: 1523-1747
CID: 5410552
Multiple eruptive dermatofibromas in an adolescent with a history of pityriasis lichenoides et varioliformis acuta [Case Report]
Haber, Jessica S; Meehan, Shane; Orlow, Seth J
PMCID:8816644
PMID: 35141383
ISSN: 2352-5126
CID: 5176102
Multifocal ulcerations in extreme prematurity
Weed, Jason G.; Brinster, Nooshin K.; Oza, Vikash S.; Orlow, Seth J.
SCOPUS:85121803850
ISSN: 0736-8046
CID: 5144002
Biophysical Compatibility of a Heterotrimeric Tyrosinase-TYRP1-TYRP2 Metalloenzyme Complex
Lavinda, Olga; Manga, Prashiela; Orlow, Seth J; Cardozo, Timothy
Tyrosinase (TYR) is a copper-containing monooxygenase central to the function of melanocytes. Alterations in its expression or activity contribute to variations in skin, hair and eye color, and underlie a variety of pathogenic pigmentary phenotypes, including several forms of oculocutaneous albinism (OCA). Many of these phenotypes are linked to individual missense mutations causing single nucleotide variants and polymorphisms (SNVs) in TYR. We previously showed that two TYR homologues, TYRP1 and TYRP2, modulate TYR activity and stabilize the TYR protein. Accordingly, to investigate whether TYR, TYRP1, and TYRP2 are biophysically compatible with various heterocomplexes, we computationally docked a high-quality 3D model of TYR to the crystal structure of TYRP1 and to a high-quality 3D model of TYRP2. Remarkably, the resulting TYR-TYRP1 heterodimer was complementary in structure and energy with the TYR-TYRP2 heterodimer, with TYRP1 and TYRP2 docking to different adjacent surfaces on TYR that apposed a third realistic protein interface between TYRP1-TYRP2. Hence, the 3D models are compatible with a heterotrimeric TYR-TYRP1-TYRP2 complex. In addition, this heterotrimeric TYR-TYRP1-TYRP2 positioned the C-terminus of each folded enzymatic domain in an ideal position to allow their C-terminal transmembrane helices to form a putative membrane embedded three-helix bundle. Finally, pathogenic TYR mutations causing OCA1A, which also destabilize TYR biochemically, cluster on an unoccupied protein interface at the periphery of the heterotrimeric complex, suggesting that this may be a docking site for OCA2, an anion channel. Pathogenic OCA2 mutations result in similar phenotypes to those produced by OCA1A TYR mutations. While this complex may be difficult to detect in vitro, due to the complex environment of the vertebrate cellular membranous system, our results support the existence of a heterotrimeric complex in melanogenesis.
PMCID:8114058
PMID: 33995009
ISSN: 1663-9812
CID: 4876532
Topical corticosteroid use for atopic dermatitis in the pediatric emergency department
Wang, Jason F; Young, Trevor K; Melnick, Laura E; Orlow, Seth J; Oza, Vikash S
BACKGROUND/OBJECTIVES/OBJECTIVE:To investigate the evaluation and management of atopic dermatitis (AD) in the pediatric emergency department (PED). METHODS:This retrospective chart review was performed at the PED of a single institution and examined data from 2012 to 2017. Of 335 visits from patients 18Â years and younger coded for AD, 167 visits with documented findings that supported a diagnosis of AD according to guidelines from the American Academy of Dermatology were included. RESULTS:The mean age of presentation was 6.3Â years (standard deviation [SD]: 5.9). Of 11 patients with multiple visits, the mean between-visit interval was 31Â days (SD: 41). Topical corticosteroids (TCSs) were not prescribed or recommended in 63/167 visits. In an additional 46/167 visits, over-the-counter topical hydrocortisone was recommended. Of prescribed TCS, the mean TCS class was 5.5 (SD: 1.9). 61/104 recommended or prescribed TCSs were weak (Class 7), the most likely used class (PÂ <Â .001). Dermatology consultation was requested in 14/167 visits and was associated with higher rates of TCS prescriptions (13/14 vs 91/153, PÂ =Â .018), a higher mean class of TCS prescribed (3.1 vs 5.9, PÂ <Â .001), higher prescription rates of systemic antibiotics (8/14 vs 10/153, PÂ <Â .001), and higher recommendation rates for emollient usage (10/14 vs 46/153, PÂ =Â .005). CONCLUSIONS:Most patients presenting to the PED for AD were either not prescribed a TCS or were prescribed a weak TCS, often one that is over-the-counter. While there may be a variety of explanations for these findings, it is possible they reveal a practice gap regarding AD management in the PED.
PMID: 33870556
ISSN: 1525-1470
CID: 4846692
Melanocyte stress response pathways in the onset of vitiligo [Meeting Abstract]
Manga, P; Vega, M; Orlow, S J
Vitiligo is an acquired condition that affects about 1% of the world's population and is defined by macular depigmentation of the skin that develops following melanocyte death. Vitiligo has a significant impact on both the physical and mental health of patients. While autoimmune-mediated destruction of melanocytes ultimately leads to depigmentation, the mechanisms that promote vitiligo onset remain poorly defined. We have been investigating the hypothesis that melanocytes from individuals genetically prone to develop vitiligo are less efficient in protecting against cellular traumas such as chemical exposure, which triggers an immune response against them. We delineated the response of melanocytes from normally pigmented individuals (NMs) to challenge with the topical agent monobenzone (monobenzyl ether of hydroquinone or MBEH). Three key stress response pathways were activated by MBEH exposure: the unfolded protein stress response (UPR), the NRF2-regulated antioxidant response and the nuclear factor-kappa B (NFkappaB) pathway. We established a key role for the UPR and NRF2 pathways in determining melanocyte viability and demonstrated disruption of their activity in melanocytes from individuals who developed vitiligo (VMs). We further showed that the NFkappaB pathway contributes to an increase in expression of IL6 and IL8 following NM exposure to MBEH and that expression of these chemokines is higher in VMs compared to NMs. These chemokines can promote an autoimmune response. We have now used transcriptome analysis to identify additional stress response pathways that are dysfunctional in vitiligo. Our data suggest that multiple signaling pathways that protect cells against trauma and facilitate a return to homeostasis are disrupted in VMs and may cause these cells to be targeted by the immune system
EMBASE:634525352
ISSN: 1755-148x
CID: 4828112
Psychiatric Disorders and Suicidal Behavior in Patients with Acne Prescribed Oral Antibiotics versus Isotretinoin: Analysis of a Large Commercial Insurance Claims Database
Ugonabo, Nkemjika; Love, Elyse; Wong, Priscilla W; Rieder, Evan A; Orlow, Seth J; Kim, Randie H; Nagler, Arielle R
BACKGROUND:The association between isotretinoin and psychiatric disturbance, including depression and suicidal behavior, is controversial. OBJECTIVE:To investigate whether acne patients prescribed isotretinoin or antibiotics were more likely to have psychiatric disorders and/or engage in suicidal behavior. METHODS:Retrospective cohort study identified acne patients prescribed isotretinoin or oral antibiotics in the IBM® MarketScan® Databases of commercial US insurance claims data from 2011-2017 who were also diagnosed with psychiatric disorders or suicidal behavior. RESULTS:A total of 72,555 patients were included. Compared to acne patients prescribed isotretinoin, patients in the general population were 1.47 times more likely to be diagnosed with suicidal ideation or attempt (adjusted OR 1.47; 1.27, 1.70, p <.0001). However, the general population (adjusted OR 0.87; 0.84, 0.89, p<0.0001) and acne patients prescribed antibiotics (adjusted OR 0.88; 0.85, 0.91, p<0.0001) were less likely to have a psychiatric diagnosis compared to acne patients prescribed isotretinoin. The prevalence of suicidal behavior during isotretinoin treatment was lower (0.10%) (p=0.082), than during the year prior to (0.22%) and during the year after isotretinoin treatment (0.34%), (p = 0.004). LIMITATIONS/CONCLUSIONS:Study excludes individuals with public or no insurance and relies on physician coding accuracy. CONCLUSIONS:Compared to the general population, acne patients prescribed isotretinoin were less likely to engage in suicidal behavior. Further exploration is warranted into the slight increase in suicidal behavior seen in isotretinoin patients one year after therapy.
PMID: 33727021
ISSN: 1097-6787
CID: 4817712